National Institute for Health and Clinical Excellence

Health written question – answered on 12th November 2010.

Alert me about debates like this

Photo of John Leech John Leech Liberal Democrat, Manchester, Withington

To ask the Secretary of State for Health with reference to his Department's announcement of 1 November 2010 on the future role of the National Institute for Health and Clinical Excellence, whether the cost-effectiveness element of the health technology appraisal will be phased out prior to the planned introduction of value-based pricing.

Photo of Simon Burns Simon Burns The Minister of State, Department of Health

Prior to the proposed introduction of value-based drug pricing from January 2014, we expect that the National Institute for Health and Clinical Excellence (NICE) will continue to appraise the clinical and cost-effectiveness of specific drugs and treatments.

Our plans for value-based pricing aim to ensure that clinically effective drugs are also cost-effective, with the national health service paying a price that reflects the value of a drug to patients. As we develop and implement our plans for value-based drug pricing, NICE's role will inevitably evolve with NICE continuing to have an important advisory role, including in assessing the clinical benefits of new medicines. We will be consulting shortly on our plans for value-based pricing.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.